The prognostic impact of U2AF35 mutations is also a controversial issue in myeloid malignancies [2, 34-37, 52], while SRSF2 mutations have a negative impact on MDS, MDS/MPN or MPN survival and MDS disease progression [34, 35, 37, 38, 53-55]. This evidence concerns the gene SRSF2 and myeloproliferative disorder.